Form 4: United Therapeutics' President and COO, Michael Benkowitz, Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Michael Benkowitz, President and COO of United Therapeutics, executed stock options and sold shares of common stock on January 6, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On January 6, 2025, Michael Benkowitz, the President and COO of United Therapeutics, exercised stock options and sold shares of the company's common stock.
- These transactions were executed under a Rule 10b5-1 trading plan that was established on August 7, 2024.
- The transactions involved the exercise of options with an exercise price of $111.
- The sales of common stock occurred at various prices, ranging from approximately $353.35 to $358.42 per share.
- The shares were held in trusts beneficially owned by Benkowitz, with some trusts also including family members as beneficiaries.
- After these transactions, Benkowitz continues to beneficially own shares of United Therapeutics common stock, both directly and indirectly through trusts.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's future prospects.
Future Outlook
The reporting person will continue to execute trades under the Rule 10b5-1 trading plan.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These filings are monitored by investors to gain insights into management's perspective on the company's stock.
Comparison to Industry Standards
- Tracking insider transactions is a common practice among investors to gauge sentiment.
- Companies like Pfizer, Johnson & Johnson, and Amgen also have executives who regularly file Form 4s related to stock options and sales.
- The use of 10b5-1 plans is a standard method for insiders to sell shares while avoiding accusations of trading on non-public information.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
- The impact on employees, customers, suppliers, and creditors is likely to be negligible.
Key Dates
| Date | Description |
|---|---|
| 2021-03-15 | Original date of exercisable stock options. |
| 2024-08-07 | Date of adoption of the Rule 10b5-1 trading plan. |
| 2025-01-06 | Date of stock option exercise and share sales. |
| 2025-01-07 | Date of signature for the Form 4 filing. |
| 2028-03-15 | Expiration date of stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.